References
Patick, A. K., Boritzki, T. J., Bloom, L. A.: Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfnavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infectionin vitro. Antimicrob. Agents Chemother. 41 (1996) 2159–2164.
Peterson, A. K., Gersten, M., Knowles, M., Chang, Y., Yu, G., Clendeninn, N. J. (Agouron Pharmaceuticals, La Jolla, CA) for the Viracept Cooperative Study Group: Long-term virological and immunological response to treatment with viracept (nelfinavir mesylate) in combination with zidovudine and lamivudine. Program and abstracts of the Sixth European Conference on Clinical Aspects of HIV-Infection, Hamburg, Germany 1997, abstr. no. 210.
Nelfinavir prescribing information. Agouron Pharmaceuticals Inc., La Jolla, CA, USA.
McDonald, C. K., Kuritzkes, D. R.: Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157 (1997) 951–959.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grunke, M., Kraetsch, H.G., Löw, P. et al. Nelfinavir associated with peripheral neuropathy in an HIV-infected patient. Infection 26, 252 (1998). https://doi.org/10.1007/BF02962377
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02962377